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Abstract 
In vitro cellular senescence of human umbilical vein endothelial cells (HUVEC) may involve the intracellular activity of 
the signal peptide-less cytokine interleukin (IL)- 1 or. To determine whether senescence of other human diploid cells involves 
the function of IL-1 a, we examined the steady-state expression of IL-1 cr mRNA in IMR-90 fibroblasts. The IL-1 a 
transcript was not elevated in senescent IMR-90 cells. With the exception of the plasminogen activator inhibitor (PAl)-1 
transcript, other IL-1 or-response gene mRNAs were not induced in senescent IMR-90, although the mRNA for each gene 
was induced by exogenous IL-1 a. The mRNA expression of cell cycle-specific genes demonstrated that Fos and ornithine 
decarboxylase (ODC) were induced in young and senescent cells in response to both serum and fibroblast growth factor 
(FGF)-1. Histone (H)3 mRNA was induced by serum in young cells, but not in senescent cells, and FGF-1 failed to induce 
H3 mRNA in either young or senescent cells. Further, while young IMR-90 populations were able to respond to serum as an 
initiator of DNA synthesis and cell growth, they did not exhibit a response to exogenous FGF-1. FGF receptor (R)-I 
substrates were not tyrosine phosphorylated in either young or senescent IMR-90 cells. These data demonstrate hat IL-1 a 
and FGF-1 may have different functions in HUVEC and IMR-90 fibroblast populations including distinct pathways for the 
regulation of cellular growth and senescence. 
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1. In t roduct ion  
Abbreviations: Cox, cyclooxygenase; CPD, cumulative popu- 
lation doubling; FGF, fibroblast growth factor; FGFR, receptor; 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; H, histone; 
HDF, human diploid fibroblasts; HUVEC, human umbilical vein 
endothelial cells; IL, interleukin; MnSOD, magnesium superox- 
ide dismutase; ODC, ornithine decarboxylase; PAl, plasminogen 
activator inhibitor; RTPCR, reverse transcriptase polymerase 
chain reaction; uPA, urokinase. 
* Corresponding author. Fax: + 1 301 7380465. 
Human diploid fibroblasts (HDFs) undergo the 
process of cellular senescence in vitro after approx. 
60 cumulative population doublings (CPD) [1]. Al- 
though senescent HDFs remain viable and synthesize 
RNA and protein [2], they no longer respond to 
mitogenic stimuli [3]. The CPD level at which cellu- 
lar senescence occurs is inversely related to the age 
of the donor [4], suggesting that factors which regu- 
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late cellular senescence in vitro may provide insight 
into the aging process in vivo. 
The loss of the proliferative potential for senescent 
cells may be due to a decreased response to growth 
factors and/or an increased response to inhibitory 
factors. Early passage HDFs have been shown to 
proliferate in response to the prototypic members of 
the fibroblast growth factor (FGF) gene family, FGF-1 
and FGF-2 [5-8], as well as to the interleukin (IL)-I 
family members, IL-1 c~ and IL-1/3 [5,9]. Although 
the primary sequence of the FGF and IL-1 prototypes 
are only weakly related [10], the FGF and IL-1 
prototypes lack a classical signal peptide sequence to 
direct their secretion through the endoplasmic reticu- 
lum-Golgi apparatus. In addition, recent crystallo- 
graphic data have demonstrated structural similarities 
[11] suggesting that homologous regions between 
these proteins may share common functional proper- 
ties. Indeed, it has been demonstrated that exposure 
of human dermal fibroblasts to both FGF and IL-1/3 
resulted in a synergistic proliferative response [5]. 
However, this effect appeared restricted to prolifera- 
tion since other IL-1/3-induced effects were inhibited 
in the presence of the FGF. 
The ability of the FGF and IL-1 prototypes to 
modulate differential effects on human fibroblasts is 
consistent with their opposite effects on human um- 
bilical vein endothelial cells (HUVEC). Although 
FGF-1 is a potent mitogen for HUVEC, its function 
is antagonized in the presence of extracellular IL-1 c~. 
Our laboratory has previously shown an exaggerated 
level of intracellular IL-1 a in senescent HUVEC that 
is strain-specific [12] and the high levels of IL-1 
may function to repress FGF-l-induced HUVEC 
growth [13] and migration in senescent populations 
(J. Cell Biol., 1996, in press). Further, Kumar et al. 
[14] demonstrated an unexpected elevation of IL-1 a 
and IL-I c~-response genes in non-proliferative s nes- 
cent human IMR-90 fibroblasts, despite the observa- 
tion that extracellular IL-1 o~ may function as a fi- 
broblast mitogen. The biological significance of IL- 
l o~ expression in senescent fibroblasts is unknown, 
however, given that extracellular IL-1 a will inhibit 
FGF-l-induced endothelial cell proliferation and 
senescent HUVEC possess high intracellular levels of 
IL-1 c~, we have begun to question whether human 
senescent cell populations possess defects in their 
FGF-1 signal transduction pathways. 
Prior studies with senescent fibroblasts [15,49,50] 
have shown that Fos induction in response to serum 
was repressed as compared to the serum induction in 
young fibroblasts, indicating that a defect in the 
immediate-early component of receptor signaling 
pathways may exist. Although there does not appear 
to be differences between young and senescent fi- 
broblast populations in the number or affinity of 
growth factor receptors [16-18], the protein tyrosine 
kinase activity, as exemplified by the autophospho- 
rylation of the epidermal growth factor receptor, ap- 
pears to be compromised in senescent WI-38 fibrob- 
lasts [19]. Studies from our laboratory identified two 
predominant yrosine phosphorylated proteins in 
FGF-l-treated BALB/c 3T3 cells during the imme- 
diate-early and mid-to-late G1 phase of the cell cycle 
[20] which include Src [21] and the murine homolog 
of the chicken cortactin gene, a substrate for v-src 
[22]. Because senescent cells are thought to be blocked 
at the late G 1 or G1/S border [18,23], the phosphory- 
lation states of these proteins may identify FGF-1 
responsiveness of various cell types through the FGF- 
1 receptor (R) signal transduction pathway. 
In this report we have studied the role of IL-1 c~ 
and FGF-1 in promoting human fetal lung IMR-90 
fibroblast senescence in vitro. Although IL-1 c~ levels 
were previously shown to be elevated in senescent 
IMR-90 fibroblasts [14], we were unable to detect he 
steady-state ranscript in young or senescent IMR-90 
cells, but found that the transcript was induced by 
exogenous IL-1 a in both cell populations. Of the 
IL-lc~-response genes, only plasminogen activator 
inhibitor (PAI)-I mRNA levels were elevated in the 
senescent IMR-90 cells. In addition, Fos and or- 
nithine decarboxylase (ODC) mRNAs were induced 
in response to serum and FGF-1 in both young and 
senescent fibroblasts. However, the histone (H)3 
mRNA was induced by serum in young cells but not 
in senescent cells, and was not induced by FGF-1 in 
either young or senescent cells. Further, we did not 
observe tyrosine phosphorylation of FGFR-1 sub- 
strates in either young or senescent cells, nor did we 
see a significant growth response to FGF-1 in young 
populations. These results suggest hat the elevation 
of IL-1 c~ mRNA does not appear to be involved in 
promoting IMR-90 cellular senescence and a block to 
FGF-1 following the early-to-mid G, phase was ob- 
served in both young and senescent populations. Thus, 
S. Garfinkel et al. /Biochimica et Biophysica Acta 1314 (1996) 109-119 111 
the role of IL-1 a and FGF-1 in IMR-90 fibroblasts 
appears to differ from their role in HUVEC, suggest- 
ing that distinct pathways to cellular senescence exist 
in these different mesoderm-derived c ll types. 
2. Materials and methods 
2.1. Reagents and probes 
Phorbol 12-myristate 13-acetate (PMA) was ob- 
tained from Sigma. Recombinant human IL-1 a was 
a kind gift of P. Lomedico (Hoffmann-LaRoche), the 
human PAI-1 cDNA probe was kindly provided by 
D. Loskutoff (Scripps Research Institute). The human 
cDNA for Fos and glyceraldehyde-3-phosphate dehy- 
drogenase (GAPDH) were purchased from the Amer- 
ican Type Culture Collection. The H3 and ODC 
genes were generous gifts from J. Campisi (Univer- 
sity of California at Berkeley) and J.K. deRiel (Tem- 
ple University). Immunoblot analyses were per- 
formed with various antibodies: polyclonal rabbit 
anti-mouse cortactin antisera #2719, generated from 
peptide antigen (residues 343-362 of murine cor- 
tactin) injected into rabbits [22] and anti-cortactin 
antisera #001, generated from recombinant murine 
cortactin expressed as a glutathione S-transferase fu- 
sion protein; monoclonal anti-phosphotyrosine (Up- 
state Biotechnology Inc., Lake Placid, NY); poly- 
clonal rabbit anti-human Src (N-16), an antibody 
raised against a peptide corresponding to the unique 
residues 3-18 within the amino terminus of the hu- 
man Src gene and anti-Src (Src-2), a polyclonal 
antibody raised against a peptide corresponding to the 
carboxyl-terminus of Src and cross-reactive with Yes 
and Fyn (Santa Cruz Biotechnology, Santa Cruz, 
CA). ot-[32p]dCTP (3000 Ci/mmol) and [3H]thymi- 
dine (25 Ci/mmol) were purchased from NEN. Re- 
combinant human FGF-1 was prepared as previously 
described [24]. 
2.2. Cells and tissue culture 
Human fetal lung IMR-90 fibroblasts were pur- 
chased from the NIA Aging Cell Culture Repository, 
Coriell Institute for Medical Research (Camden, N J). 
IMR-90 cells were serially passaged at 1:3 split ratios 
in Medium M199 (Mediatech) supplemented with 
10% (v/v) fetal bovine serum (FBS) (HyClone) and 
lx antibiotic-antimycotic (Gibco). At each passage 
when confluent, the cells were harvested by trypsin 
digestion, counted in a hemacytometer and seeded at 
known cell densities. The number of population dou- 
blings was calculated as described [24]. Cells with 
less than 30 cumulative population doublings (CPDs) 
corresponding to a passage number less than 12, were 
considered young. For most of the experiments per- 
formed, young cells were at CPD 20 corresponding to 
passage 8. Cells considered senescent achieved greater 
than 58 CPDs, corresponding to passage number 27 
or higher, and were maintained in culture for a 
minimum of 10 days without an increase in cell 
number. The senescent cells used in the experiments 
completed at least 95% of their lifespan. 
Thymidine incorporation assays were performed 
with cells plated on 24-well plates and grown to 
confluence. The cells were made quiescent by starva- 
tion in serum-free media (DMI; 8 mM NaHCO3, 15 
mM Hepes (pH 7.4), 4 /xM MnCI2, 2.5 mM histi- 
dine, 10 /xM ethanol-amine, 0.1 /xM sodium selen- 
ite, 5 mg/1 transferrin, 500 mg/1 linoelic acid, 10 
/xg/ml insulin) for 48 h and then treated for 24 h 
with FGF-1 at the indicated concentrations and hep- 
arin (5U/ml, Sigma) or 10% serum. During the last 4 
h of treatment, [3H]thymidine (0.5 /zCi/well) was 
added. The cells were washed with PBS and then 0.5 
ml cold 10% trichloroacetic acid (TCA). The TCA 
was decanted and TCA-precipitable material rinsed 
with PBS, solubilized with 0.5 ml 0.2 N NaOH and 
neutralized with 0.5 ml 0.2 N HC1. The radioactivity 
was measured by liquid scintillation. 
HUVEC were serially passaged in M199 contain- 
ing 10% (v/v) FBS, 1 X antibiotic-antimycotic 
(GIBCO), 5U/ml  heparin (Upjohn) and crude bovine 
FGF-1 (150 /zg/ml) in cell culture dishes coated 
with fibronectin (5/zg/cm2). HUVEC growth assays 
were performed with cells plated at low cell densities 
(2 X 103 cells/cm 2) grown in M199, 10% FBS and 
1 x antibiotic in the presence or absence of purified, 
recombinant FGF-1 and heparin (10 /xg/ml) as indi- 
cated. Growth assays with IMR-90 cells were per- 
formed in starvation media (DMEM with either 0.5% 
FBS or 3% FBS and antibiotic) plated at low cell 
densities (2X 103 cells/cm2). Each sample was 
grown in triplicate and, at the indicated times, 
trypsinized and counted in a Coulter Counter. 
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2.3. RNA extraction and Northern blot analysis 
Total RNA was extracted from cell monolayers by 
the guanidinium isothiocyanate procedure as de- 
scribed [25]. The concentration of the purified RNA 
was determined by absorbance at 260 nm and the 
integrity of the RNA was analyzed by agarose gel 
electrophoresis and ethidium bromide staining. The 
RNA (10 /zg) was separated on 0.8% agarose gels 
and capillary-blotted onto Zeta-Probe nylon mem- 
branes (Bio-Rad). 32p-labeled cDNA probes were 
hybridized to the RNA at 65°C for 16 h [26]. The 
membranes were washed at high stringency and ex- 
posed on Kodak X-AR film at -80°C. 
2.4. Reverse transcriptase-polymerase chain reac- 
tions (RT-PCR) 
RT-PCR was performed as described [25] using 1 
/zg total RNA. The cDNA was diluted to 500/zl with 
H20 and PCR was performed with 20 /xl of each 
sample amplified for 35 cycles: denaturation at94°C 
for 1 min, annealing at 54°C for 2 min and extension 
at 72°C for 3 min. This was followed by elongation at 
72°C for 10 min. Specific primer sequences for each 
gene were as follows: cyclooxygenase (Cox)-2: sense: 
5'-TTC AAA TGA GAT TGT GGG AAA AT-3', 
antisense: 5'-AGA TCA TCT CTG CCT GAG TAT 
CTT-3'; IL-1/3: sense: 5'-GAC TTG TTC TTT GAA 
GCT GAT-3', antisense: 5'-CTG TAG AGT GGG 
CTT ATC ATC TTT C-3'; I L - la :  sense: 5'-GTT 
CCA GAC ATG TTT GAA GAC CTG-3', antisense 
5'-TGG ATG GGC AAC TGA TGT GAA ATA-3'; 
Fos: sense: 5'-GGC TTC AAC GCA GAC TAC 
GAG G-3', antisense: 5'-GAG TCA GAG GAA GGC 
TCA TT-3'; GAPDH: sense: 5'-CCA CCC ATG GCA 
AAT TCC ATG GCA-3', antisense: 5'-TCT AGA 
CGG CAG GTC AGG TCC ACC-3'. 
2.5. Immunoblot analysis 
Confluent monolayers of IMR-90 cells were used 
to prepare cell lysates for immunoprecipitation with 
specific antibodies as described in the text. Cells 
were washed one time with cold phosphate buffered 
saline (PBS) containing 1 mM Na3VO 4. The cells 
were scraped into 1 ml PBS and collected by cen- 
trifugation (5 s) in a microfuge. Cell pellets were 
lysed in 1 ml RIPA buffer (10 mM Tris-HC1 (pH 
7.5), 1 mM EDTA, 150 mM NaC1, 0.1% SDS, 0.5% 
sodium deoxycholate, 1% Triton X- 100) containing 1
mM phenylmethylsulfonyl fluoride (PMSF), 2 /xg /ml  
aprotinin, 10 /xg/ml leupeptin and 1 mM Na3VO 4 
and incubated on ice for 5 min. The cell lysate was 
centrifuged at 4°C for 10 min and the supernatants 
were transferred to a fresh tube. Specific antibodies 
were added as described and cell lysates were rotated 
at 4°C for 1 h followed by the addition of 20 /xl 
Protein A-Sepharose (Pharmacia LKB Biotechnology 
Inc.) and rotated at 4°C for 1 h. Immunoprecipitates 
were washed three times with RIPA buffer, dissolved 
in 50 /zl SDS sample buffer (125 mM Tris-HC1 (pH 
6.8), 2% SDS, 10% glycerol, 0.001% bromophenol 
blue) and resolved by SDS-PAGE using 7.5% (w/v) 
acrylamide gels. The proteins were transferred to a 
0.2 /xm nitrocellulose membrane (Schleicher and 
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Fig. 1. IL-1 a and IL-1 tx-response g ne mRNA expression i
young and senescent HDFs. A. Monolayers of young (Y) and 
senescent (S) IMR-90 cells were untreated (lanes 1 and 3) or 
treated (lanes 2 and 4) with l0 ng/ml of recombinant IL-1 a for 
4 h. Total RNA was purified and used for RT-PCR with sense 
and antisense primers pecific for IL-la, IL-1/3 or Cox-2 (see 
Section 2). The products of amplification were separated ona 1% 
agarose gel and stained with ethidium bromide. Amplification of
the same cDNA with primers specific for GAPDH confirmed that 
similar amounts ofRNA were reverse transcribed. B. Total RNA 
was isolated from young (Y) or senescent (S) IMR-90 cells that 
were untreated (lanes 1 and 3) or treated (lanes 2and 4) with 10 
ng/ml IL-1 a for 4 h. Total RNA was purified and separated on
0.8% agarose gels. Northern blot analysis was performed using 
PAI-1 and GAPDH [32p]-labeled cDNA probes. 
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Fig. 2. mRNA expression of cell cycle-specific genes in young and senescent populations of HDFs. A. Panel 1, young (Y) and senescent 
(S) cultures of IMR-90 cells were starved in 0.5% serum for 48 h and then stimulated with FGF-1 (10 ng/ml)  and heparin (10 /xg/ml) or 
10% serum where indicated. Total RNA was purified and used for RT-PCR with sense and antisense primers for human Fos cDNA (see 
Section 2). The products of amplification were separated on 1% agarose gels and stained with ethidium bromide. RT-PCR with the same 
cDNA using GAPDH-specific primers confirmed that similar amounts of RNA were reverse transcribed. Panel 2, young (Y) and 
senescent (S) IMR-90 cells were starved for 72 h, treated with FGF-1 or serum and RT-PCR was performed as described above. Panel 3, 
young (lanes 1 to 4) and senescent (lanes 5 to 8) IMR-90 cells were starved in 0.2% FBS for 60 h and stimulated with 15% serum for 30 
min (lanes 2 and 6), 60 min (lanes 3 and 7) or 90 min (lanes 4 and 8), at which time RNA was extracted and used for RT-PCR assays. 
Panels 1, 2 and 3 represent lhree separate RNA preparations. B. young (Y) and senescent (S) cultures of IMR-90 cells were starved in 
DMI for 48 h or 72 h. Following starvation, FGF-I (10 ng/ml)  and heparin (10 /xg/ml) or 10% serum was added for 1 h or 24 h where 
indicated. Total RNA was purified and separated on 0.8% agarose gels for Northern blot analysis using 32p-labeled cDNA probes specific 
for human ODC or murine histone 3.2. The blot was rehybridized to a GAPDH cDNA probe to confirm that the samples contained 
similar levels of RNA. 
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Schuell) and Western blot analysis was performed 
with specific antibodies using enhanced chemilumi- 
nescence (Amersham) according to the manufacturer's 
instructions. 
3. Results 
3.1. Expression of IL-la and IL-la-response gene 
mRNAs in IMR-90 human diploid fibroblasts 
Previous studies from our laboratory have demon- 
strated an elevation of the steady-state l vel of IL-1 a 
mRNA in senescent HUVEC populations [12,13]. 
Because this was strain specific in HUVEC and 
involved post-transcriptional events for the regulation 
of intracellular I L - la  [12], we attempted to deter- 
mine whether IL-1 a was involved in the regulation 
of the senescent phenotype for normal HDFs. Total 
RNA was extracted from young and senescent popu- 
lations of IMR-90 fibroblasts. RT-PCR or Northern 
blot analysis was performed using specific primers or 
probes for IL-1 a or for the IL-1 a-response genes, 
IL-1/3, Cox-2 and PAI-1, and for the constitutively 
expressed GAPDH gene (Fig. 1). The steady-state 
mRNA levels for IL - la ,  IL-1/3 and Cox-2 were 
barely detectable in either young or senescent popula- 
tions. Because these transcripts were efficiently am- 
plified in both cell populations treated with exoge- 
nous IL - la ,  we suggest that these transcripts are 
easily detected in this assay when sufficient amounts 
of mRNA are present. Northern blot analysis for the 
IL-la-response genes, superoxide dismutase and 
urokinase, also did not show an elevated steady-state 
mRNA level in senescent populations (data not 
shown). However, the mRNA level for PAI-1 was 
elevated in the senescent HDF population and was 
not further induced by treatment with exogenous 
IL-1 a (Fig. 1B), consistent with the results of others 
[42] and our results observed in senescent HUVEC 
[12]. These data demonstrate that in contrast o the 
elevated steady-state l vel of IL-1 a mRNA and IL- 
l a-response genes in senescent HUVEC [12], the 
steady-state mRNA levels of IL-1 a, IL-113 and Cox-2 
do not appear to be elevated in the senescent popula- 
tions of IMR-90 fibroblasts. 
3.2. Cell cycle-specific mRNA expression in young 
and senescent fibroblasts 
Because our results did not demonstrate a correla- 
tion between elevated steady-state l vels of the IL-1 a 
transcript and senescence of IMR-90 fibroblasts, we 
analyzed the expression of other genes that have been 
implicated in the regulation of human fibroblast 
senescence. It has been suggested that Fos transcrip- 
tion is repressed in senescent WI-38 human fetal lung 
fibroblasts in response to serum [15,49,50], poten- 
tially explaining the failure of these senescent cells to 
proliferate. However, using Fos-specific primers for 
Fig. 3. Tyrosine phosphorylation of Src and cortactin and DNA synthesis in HDFs in response to FGF-1 and serum. A,B. Monolayers of 
young and senescent IMR-90 cells were starved in serum-free media for 48 h then stimulated for 6 h with FGF-I (10 ng/ml) and heparin 
(10 /zg/ml) or with 10% serum. Cell lysates were prepared and equal amounts of lysates were subjected to immunoprecipitation with 
antibodies pecific for Src (panel A) or cortactin (panel B). Upper panels, the precipitates were fractionated by SDS-PAGE on 7.5% gels 
and analyzed for their phosphotyrosine content by immunoblot analysis using a monoclonal ntibody against phosphotyrosine. Lower 
panels, the same immunoprecipitates w re analyzed for Src or cortactin protein levels by immunoblot analysis using anti-Src (an antibody 
which recognizes Src and Src-related proteins) or anti-cortactin (an antibody raised against recombinant murine cortactin). C. Quiescent 
monolayers of young IMR-90 cells (CPD 27) were stimulated with various amounts of FGF-1 and 10 /zg/ml heparin or 10% serum for 
24 h. [3H]thymidine was added to the cultures during the last 4 h of treatment and the level of DNA synthesis was quantitated in triplicate 
samples by [3H]thymidine incorporation as described in Section 2. D. Monolayers of IMR-90 cells (CPD 18) were plated at low cell 
densities (2.08 × 104 cells/cm 2) in complete growing media as described in Section 2. Following 24 h, the cells were washed with PBS 
and starvation media, containing FGF-1 (10 ng/ml) and heparin (10 ~g/ml), was added to the IMR-90 cells (DMEM, 0.5% FBS, 
antibiotic) and HUVEC (M199, 10% FBS, antibiotic). The samples were grown in triplicate and counted with a Coulter Counter on the 
indicated ays. E. Confluent monolayers of IMR-90 cells (CPD 23) or HUVEC (CPD 17) were grown for 24 h in DMEM, 3% FBS and 
antibiotic or M199, 10% FBS and antibiotic, respectively. The cells were washed with PBS, trypsinized and plated at low cell densities 
(2.08 × 104 cells/cm 2) in their starvation media containing heparin (10/xg/ml) and various amounts of FGF-1 as indicated. HUVEC 
were grown for 10 days and the IMR-90 cells were grown for 12 days, at which time the cells were trypsin-treated and counted in a 
Coulter Counter. The data represent the average of triplicate cultures. 
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RT-PCR analysis, on three separate preparations of 
mRNA, we observed that the steady-state l vel of Fos 
mRNA was induced by serum in both young and 
senescent IMR-90 fibroblasts (Fig. 2A). Further, the 
amplified bands were transferred to nylon membranes 
and probed with (32p)-labeled Fos-specific cDNA to 
confirm that the ethidium stained band corresponded 
to the Fos gene (data not shown). 
Because cell cycle-specific gene expression has 
been used as a marker of cell progression through the 
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G 1 and S phases in response to growth factors, we 
analyzed the mRNA expression of ODC, a mid GI- 
specific gene, and H3, an S-phase-specific gene. Pub- 
lished reports [15,27,28] have demonstrated that the 
expression of ODC is induced in both young and 
senescent populations of HDFs in response to serum, 
however, H3 is induced by serum only in young 
populations. Our analysis (Fig. 2B) confirms the 
serum induction of ODC and H3 expression in IMR- 
90 fibroblasts [15,27,28]. Although the induction of 
ODC mRNA in senescent HDFs appears to be attenu- 
ated following 24 h serum treatment as compared to 
young populations (Fig. 2B), we did not rigorously 
quantitate the kinetics of ODC induction and the 24 h 
time point is only representative of the late G~/S 
phase of the cell cycle. Thus, these cells do indeed 
respond to serum in the induction of an early to mid 
G~-specific gene. 
It is well established that senescent cells in culture 
are unresponsive to extracellular signals that are nor- 
mally mitogenic, yet the number of growth factor 
receptors and their binding affinities for specific lig- 
ands do not appear to be altered [16-18,29]. Because 
FGF-1 has been reported to be a mitogen for primary 
human fibroblasts [5-7], we questioned whether 
FGF-1 would also induce the expression of Fos, ODC 
and H3. RT-PCR and Northern blot analysis howed 
that following starvation, the addition of FGF-1 in- 
duced Fos and ODC mRNA expression i  both young 
and senescent populations of IMR-90 cells (Fig. 2A 
and 2B). However, FGF-1 failed to cause the induc- 
tion of H3 mRNA in either cell population (Fig. 2B). 
3.3. FGF-l-dependent tyrosine phosphorylation is de- 
ficient in IMR-90 human diploid fibroblasts 
Although early reports uggested that the induction 
of Fos in fibroblasts was required for progression 
through the cell cycle [30-32], the ability to induce 
Fos mRNA does not necessarily correlate with cell 
proliferation [33-35,51]. Because the expression of 
cell cycle-specific genes suggested that a block to 
FGF-1 responsiveness exists in both young and 
senescent IMR-90 cells following the early to mid G~ 
phase, we questioned whether FGF-l-mediated pro- 
tein tyrosine kinase activity was functional in these 
cells. Previous studies from our laboratory identified 
two predominant tyrosine phosphorylated proteins 
with molecular weights of 80 kDa and 60 kDa in 
FGF-l-treated BALB/c 3T3 cells during the mid-to- 
late G 1 phase of the cell cycle, corresponding to 
murine cortactin and Src, respectively [20-22]. 
Young and senescent populations of IMR-90 cells 
were starved in serum-free media and then treated 
with either 10% serum or FGF-1. Lysates from these 
cells were incubated with antibodies against Src or 
cortactin, the immunoprecipitates r olved by SDS- 
PAGE and analyzed by immunoblot analysis using 
and anti-phosphotyrosine antibody. A very low level 
of phosphorylated Src was present in both young and 
senescent serum-starved IMR-90 cells, with no in- 
crease in the level of phosphorylation after cells were 
treated with either FGF-1 or serum for 6 h (Fig. 3A). 
In addition, we were unable to detect cortactin as a 
phosphotyrosine-containing protein in any of the 
lysates (Fig. 3B). Using antibodies for either Src or 
cortactin for immunoblot analysis showed that the 
levels of the specific proteins were similar in each of 
the cell lysates regardless of the treatment. The lack 
of tyrosine phosphorylation of FGFR-1 substrates 
was also observed in young and senescent cultures of 
IMR-90 cells treated for 24 h with FGF-1 or serum, 
or when the cells were made quiescent in 0.5% serum 
(data not shown). Further, no differences were obvi- 
ous in the tyrosine phosphorylation pattern on total 
cell extracts of young IMR-90 fibroblasts after FGF-1 
stimulation; however, serum induced changes in the 
phosphotyrosine pattern in this population (data not 
shown). 
To test further whether the FGF-1 responsiveness 
of young IMR-90 fibroblasts may be blocked follow- 
ing the early-to-mid G l phase of the cell cycle, we 
performed DNA synthesis assays on serum-starved 
young cell populations treated with either FGF-1 or 
10% serum. Serum-starved cells exhibited a low 
baseline level of (3H)-thymidine incorporation and a 
12-fold induction in response to serum, but surpris- 
ingly, a rather weak 4-fold response to FGF-1 (Fig. 
3C). Similar results were obtained in assays using 
young populations of IMR-90 fibroblasts treated with 
FGF-2 (data not shown). Further, standard growth 
assays with young populations of IMR-90 fibroblasts 
seeded at low cell densities, showed no significant 
growth stimulation with the addition of 10 ng/ml  
FGF-1, whereas HUVEC, which are absolutely de- 
pendent on FGF for growth, treated simultaneously, 
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showed a strong proliferative response to the addition 
of FGF-1 (Fig. 3 D and E). Moreover, the growth of 
young populations of IMR-90 fibroblasts did not 
exhibit a FGF-1 dose response (Fig. 3E) which is 
consistent with the DNA synthesis assays. 
4. Discussion 
IL-1 a and IL-1/3 are ,;ignal peptide sequence-less, 
multifunctional inflammatory cytokines produced pri- 
marily by monocytes but also found in a wide variety 
of other cell types [36]. An additional family member 
is the IL-1 receptor antagonist (RA) that is a naturally 
occurring antagonist [37]. It has been suggested that 
IL-I a and /3 may exert an intracellular function 
[38-40] and our studies have suggested that intra- 
cellular IL-1 a may contribute to the inhibition of 
human endothelial cell growth and the elevation of 
IL-1 a levels may ultimately contribute to the forma- 
tion of the senescent phenotype of HUVEC popula- 
tions in vitro [12,13,25]. Many of the early studies of 
cellular senescence examined HDFs and elevated lev- 
els of the IL-1 a transcript has recently been ob- 
served in senescent IMR-90 fibroblasts [14]. To de- 
termine the intracellular and extracellular components 
involved in promoting HDF senescence, we at- 
tempted to confirm these results, but did not observe 
an elevation of the steady-state IL-1 c~ mRNA in 
senescent IMR-90 fibroblasts or an elevation of the 
steady-state level of the IL-1 o~ response genes, IL-1/3 
or Cox-2. These results are consistent with the report 
that IL-1 a functions as a fibroblast mitogen [9] and 
thus would not likely be functional in a non-prolifera- 
tive senescent fibroblast. We cannot explain why we 
obtained ifferent results from those previously pub- 
lished [14], however, a recent report [41] using a 
novel PCR-based technique for differential display 
also failed to identify elevated IL-1 a mRNA levels 
in senescent IMR-90 fibroblasts. Interestingly, of the 
IL-1 c~-response genes that were examined, only the 
PAI-1 steady-state mRNA was elevated in both 
senescent HUVEC [12] and IMR-90 fibroblasts [42]. 
Therefore, it does not appear that its expression is 
dependent on the level of intracellular IL-1 o~ mRNA 
and the higher expression of the PAI-1 transcript in 
senescent IMR-90 fibroblasts may be regulated by a 
component of the IL-1 a signaling pathway. 
To further analyze the changes in IMR-90 fibrob- 
lasts that lead to the loss of the proliferative response 
with age in vitro, we examined the induction of cell 
cycle-specific genes. Fos and ODC mRNAs were 
induced in young and senescent IMR-90 fibroblasts 
in response to both serum and FGF-1. Although 
serum induction of the Fos transcript appears to 
contradict published data [15,49,50], these reports 
and others [52,53] do demonstrate a weak serum 
induction of Fos in senescent fibroblasts that is atten- 
uated as compared to the induction in young cell 
populations. Further, similar expression of Fos RNA 
and protein has been shown in young and senescent 
serum-stimulated cells [54]. In addition, our data 
show that the H3 transcript was induced by serum 
only in young cells, consistent with the results of 
others [15,28], and was not induced by FGF-1 in 
either young or senescent populations. However, one 
report demonstrated that H3 mRNA levels were in- 
duced by serum in senescent populations of the hu- 
man diploid WI-38 fibroblast [23]. Thus, there are 
conflicting reports in the literature on the inducibility 
of cell cycle-specific genes in senescent HDFs which 
may reflect the variability between human fibroblast 
strains obtained from different sources or may reflect 
differences in cell culture conditions [43,54]. Further, 
although we have not quantitated our RT-PCR assays 
(Fig. 2A), we have observed that the steady-state 
level of Fos mRNA is slightly reduced in unstimu- 
lated senescent IMR-90 fibroblasts, consistent with 
other reports using senescent fibroblasts [47] and also 
with the decrease in Fos and Myc mRNA observed in 
senescent human omental microvascular endothelial 
cells [44]. These data may be indicative of differential 
regulation of these oncogenes in young and senescent 
populations. Our results show that cell cycle-specific 
gene expression in response to FGF-1 is similar in 
young and senescent IMR-90 fibroblasts and appears 
to be blocked following early to mid G 1 events, since 
the expression of the H3 transcript is attenuated in
both populations. We have demonstrated that the 
induction of immediate-early or mid-to-late G1- 
specific genes by FGF-1 in senescent HUVEC is not 
sufficient to promote a proliferative phenotype 
(Garfinkel et al., In Press, J. Cell. Biol., 1996), 
suggesting that the induction of the cell cycle-specific 
genes may not be a reliable index for the proliferative 
potential of cells. This is consistent with other eports 
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demonstrating that the induction of protooncogenes 
may be related to, but not necessary for, cellular 
proliferation [34] and the expression of Fos may not 
be sufficient o relieve the cell cycle block in senes- 
cent fibroblasts [51]. Thus, we have examined FGF-1 
signaling in IMR-90 fibroblasts through the tyrosine 
phosphorylation f FGFR-1 substrates [20,22]. 
The phosphotyrosine l vel of cortactin and Src 
remains unchanged in young and senescent IMR-90 
fibroblast cells when treated with FGF-1 or serum. 
These data correlate with the lack of FGF-1 respon- 
siveness observed by DNA synthesis or growth as- 
says on young IMR-90 cells. Therefore, the early-to- 
mid G 1 function of the FGFR-1 signaling pathway in 
both young and senescent IMR-90 fibroblasts appears 
to be functional, as shown by Fos and ODC mRNA 
induction, however, neither population was respon- 
sive to FGF-l-mediated events at the mid G 1 to S 
phase of the cell cycle, as shown by H3 mRNA 
expression, tyrosine phosphorylation changes of 
FGFR-1 substrates or FGF-1-dependent DNA synthe- 
sis or growth. Our laboratory has reported that the 
interaction between FGF-1 and its receptor is a pro- 
cess that occurs continuously throughout the G 1 phase 
of the BALB/c 3T3 cell cycle [20]. Further, mutage- 
nesis of FGF-1 has demonstrated that it is possible to 
dissociate the FGFR-1 binding activity and pro- 
tooncogene expression from mitogenic activity 
[35,45,55] and our results may represent an additional 
example of the dissociation between early and late 
FGF-l-mediated cellular signaling responses. 
Interestingly, we have demonstrated that the tyro- 
sine phosphorylation f Src appears to function in the 
regulation of HUVEC growth and senescence 
(Garfinkel et al., J. Cell. Biol., submitted). In con- 
trast, a corresponding increase in the tyrosine phos- 
phorylation of Src and its substrate cortactin [21] did 
not occur in senescent IMR-90 fibroblasts. This is 
consistent with the observation that v-Src expression 
in human diploid fibroblasts neither altered the phe- 
notype nor affected the proliferative ability of the 
cells [46]. Further, both HUVEC and IMR-90 fibrob- 
lasts appear to express functional FGFR since exoge- 
nous FGF-1 is able to modify gene expression in 
these cells; however, while exogenous FGF-1 is in- 
volved in the regulation of HUVEC proliferation, it
surprisingly does not function in a similar manner in 
IMR-90 fibroblasts. Similarly, the function of intra- 
cellular IL-1 cr appears to be different in HUVEC and 
IMR-90 fibroblasts. Only the elevation of the steady- 
state human PAI-1 mRNA was observed in both 
senescent endothelial cells and fibroblasts. These data 
suggest different functions for IL-1 o~ and FGF-1 in 
human endothelial cells and IMR-90 fibroblasts. An 
antagonistic nteraction of IL-1 o~ and FGF has been 
demonstrated in endothelial cells, where IL-1 may 
cause a decrease in the expression of high affinity 
FGF binding sites [48]. However, a synergistic prolif- 
erative ffect of IL-1 and FGF has been demonstrated 
in dermal fibroblasts [5]. Thus, distinct pathways may 
ultimately lead to human endothelial cell and fibrob- 
last senescence and, at present, only the elevation of 
the steady-state l vel of PAI-1 mRNA appears to be 
common to both pathways. 
Acknowledgements 
The authors thank K. Wawzinski and D. Weber for 
expert secretarial assistance. This work was sup- 
ported by NIH Grant AG07450 to T.M. 
References 
[1] Hayflick, L. and Moorehead, P.S. (1961) Exp. Cell. Res. 25, 
585-621. 
[2] Lumpkin, C.K., McClung, J.K., Pereira-Smith, O.M. and 
Smith, J.R. (1986) Science 232, 393-395. 
[3] Phillips, P.D. and Cristofalo, V.J. (1987) Rev. Biol. Res. 
Aging 3, 385-415. 
[4] Martin, G.M., Sprague, C.A. and Epstein, C.J. (1970) Lab. 
Invest. 23, 86-92. 
[5] Clement-Lacroix, P., Friteau, L. and Damais, C. (1991) 
Lymphokine Cytokine Res. 10, 111-114. 
[6] Dubertret, L., Brunner-Ferber, F., Mitsiti, J., Thomas, K.A. 
and Dubertret, M.L. (1991) J. Invest. Dermat. 97, 793-798. 
[7] Root, L.L. and Shipley, G. (1991) In Vitro Cell. Dev. Biol. 
27A, 815-822. 
[8] Shipley, G.D., Keeble, W.W., Hendrickson, J.E., Coffey, 
R.J. and Pittelkow, M.R. (1989) J. Cell. Physiol. 138, 
511-518. 
[9] Schmidt, J.A., Mizel, S.B., Cohen, D. and Green, I. (1982) 
J. Immunol. 128, 2177-2182. 
[10] Thomas, K.A. and Gimenez-Gallego, G. (1986) TIBS 11, 
81-84. 
[11] Zhu, X., Komiya, H., Chirino, A., Faham, S., Fox, G.M., 
Arakawa, T., Hsu, B.T. and Rees, D.C. (1991) Science 251, 
90-93. 
S. Garfinkel et al. / Biochimica et Biophysica Acta 1314 (1996) 109-119 119 
[12] Garfinkel, S., Brown, S., Wessendorf, J.H.M. and Maciag, 
T. (1994) Proc. Natl. Acad. Sci. USA, 91, 1559-1563. 
[13] Maier, J.A.M., Voulalas, P., Roeder, D. and Maciag, T. 
(1990) Science 249, 1570-1574. 
[14] Kumar, S., Millis, A.J.T. and Baglioni, C. (1992) Proc. Natl. 
Acad. Sci. USA, 89, 4683-4687. 
[15] Seshadri, T. and Campisi, J. (1990) Science, 247, 205-209. 
[16] Phillips, P.D., Kuhnle, E. and Cristofalo, V.J. (1983) J. Cell. 
Physiol. 114, 311-316. 
[17] Ferber, A., Chang, C., Sell, C., Ptasznik, A., Cristofalo, 
V.J., Hubbard, K., Ozer, H.L., Adamo, M., Roberts, C.T., 
LeRoith, D., Dumenil, G. and Baserga, R. (1993) J. Biol. 
Chem. 268, 17883-17888. 
[18] Cristofalo, V.J., Phillips, P.D., Sorger, T. and Gerhard, G. 
(1989) J. Gerontol. 44, 5:5-62. 
[19] Carlin, C.R., Phillips, P.D., Knowles, B.B. and Cristofalo, 
V.J. (1983) Nature 306, 617-620. 
[20] Zhan, X., Hu, X., Friesel, R. and Maciag, T. (1993) J. Biol. 
Chem. 268, 9611-9620. 
[21] Zhan, X., Plourde, C., Hu, X., Friesel, R. and Maciag, T. 
(1994) J. Biol. Chem. 269, 20221-20224. 
[22] Zhan, X., Hu, X., Hampton, B., Burgess, W.H., Friesel, R. 
and Maciag, T. (1993) J. Biol. Chem. 268, 24427-24431. 
[23] Rittling, S.R., Brooks, K.M., Cristofalo, V.J. and Baserga, 
R. (1986) Proc. Natl. Acad. Sci. USA 83, 3316-3320. 
[24] Maciag, T., Hoover, G.A, Stemerman, M.B. and Weinstein, 
R. (1981) J. Cell Biol. 9I, 420-426. 
[25] Garfinkel, S., Haines, D.S., Brown, S., Wessendorf, J., 
Gillespie, D.H. and Maciag, T. (1992) J. Biol. Chem. 267, 
24375-24378. 
[26] Church, G.M. and Gilbert, W. (1984) Proc. Natl. Acad. Sci. 
USA 81, 1991-1995. 
[27] Chang, Z.F. and Chen, K.Y. (1988) J. Biol. Chem. 263, 
11431-11435. 
[28] Pang, J.H. and Chen, ICY. (1994) J. Cell. Physiol. 160, 
531-538. 
[29] Shimada, Y., Kaji, K., lto, H., Noda, K. and Matsuo, M. 
(1990) J. Cell. Physiol. 142, 31-38. 
[30] Muller, R., Bravo, R., Burckhardt, J. and Curran, T. (1984) 
Nature 312, 716-720. 
[31] Riabowol, K.T., Vosatka, R.J., Ziff, E.B., Lamb, N.J. and 
Feramisco, J.R. (1988) Mol. Cell. Biol. 8, 1670-1676. 
[32] Nishikura, K. and Murray, J.M. (1987) Mol. Cell. Biol. 7, 
639-649. 
[33] Imamura, T., Engleka, K,  Zhan, X., Tokita,Y., Forough, R., 
Roeder, D., Jackson, A., Maier, J.A.M., Hla, T. and Maciag, 
T. (1990) Science 249, 1567-1570. 
[34] Lampugnani, M.G., Polentarutti, N., Pedenovi, M., Manto- 
vani, A., Dejana, E. and Colotta, F. (1990) Exp. Cell Res. 
186, 381-384. 
[35] Burgess, W.H., Shaheen, A.M., Ravera, M., Jaye, M., 
Donohue, P.J. and Winkles, J.A. (1990) J. Cell. Biol. 111, 
2129-2138. 
[36] Dinarello, C. (1991) Blood 77, 1627-1652. 
[37] Eisenberg, S.P., Evans, R.J., Arend, W.P., Verderber, E., 
Brewer, M.T., Hannum, C.H. and Thompson, R.C. (1990) 
Nature 343, 341-346. 
[38] Haskill, S., Martin, G., VanLe, L., Morris, J., Peace, A., 
Bigler, C.F., Jaffe, G.J., Hammerberg, C., Sporn, S.A., 
Fong, S., Arend, W.P. and Ralph, P. (1991) Proc. Natl. 
Acad. Sci. USA, 88, 3681-3685. 
[39] Curtis, B.M., Widmer, M.B., DeRoos, P. and Quarnstrom, 
E.E. (1990)J. Immunol. 144, 1295-1303. 
[40] Wessendorf, J.H.M., Garfinkel, S., Zhan, X., Brown, S. and 
Maciag, T. (1993) J. Biol. Chem. 268, 22100-22104. 
[41] Linskens, M.H.K., Feng, J., Andrews, W.H., Enlow, B.E., 
Saati, S.M., Tonkin, L.A., Funk, W.D. and Villeponteau, B. 
(1995) Nucl. Acids Res. 23, 3244-3251. 
[42] Goldstein, S., Moerman, E.J., Fujii, S. and Sobel, B. (1994) 
J. Cell. Physiol. 161,571-579. 
[43] Watson, C.A., Camera-Benson, L., Palmer-Crocker, R. and 
Pober, J. (1995) Science 268, 447-448. 
[44] Matsuda, T., Okamura, K., Sato, Y., Morimoto, A., Ono, 
M., Kohno, K. and Kuwano, M. (1992) J. Cell. Physiol. 
150, 510-516. 
[45] Wiedlocha, A., Falnes, P.O., Madshus, I.H., Sandvig, K. 
and Olsnes, S. (1994) Cell 76, 1039-1051. 
[46] Hjelle, B., Liu, E. and Bishop, M.J. (1988) Proc. Natl. 
Acad. Sci. USA, 85, 4355-4359. 
[47] Irving, J., Feng, J., Wistrom, C., Pikaart, M. and Villepon- 
teau, B. (1992) Exp. Cell Res. 202, 161-166. 
[48] Cozzolino, F., Torcia, M., Aldinucci, D., Ziche, M., Almeri- 
gogna, F., Bani, D. and Stern, D.M. (1990) Proc. Natl. 
Acad. Sci. USA, 87, 6487-6491. 
[49] Choi, A.M.K., Pignolo, R.J., Rhys, C.M.J, Cristofalo, V.J. 
and Holbrook, N.J. (1995) J. Cell. Physiol. 164, 65-73. 
[50] Oshima, J., Campisi, J., Tannock, C.A. and Martin, G.M. 
(1995) J. Cell. Physiol. 162, 277-283. 
[51] Rose, D.W., McCabe, G., Feramisco, J.R. and Adler, M. 
(1992) J. Cell Biol. 119, 1405-1411. 
[52] DeTata, V., Ptasznik, A. and Cristofalo, V.J. (1993) Exp. 
Cell Res. 205, 261-269. 
[53] Riabowol, K., Schiff, J. and Gilman, J. (1992) Proc. Natl. 
Acad. Sci. USA 89, 157-161. 
[54] Lucibello, F.C., Brusselbach, S., Sewing, A. and Muller, R. 
(1993) Oncogene 8, 1667-1672. 
[55] Lin, Y.Z., Yao, S.Y. and Hawiger, J. (1996) J. Biol. Chem. 
271, 5305-5308. 
